Latest Biotechnology, Pharmaceutical and Healthcare News from Pharmafile

13:44 EDT 18th March 2018 | BioPortfolio

Here are the most relevant search results for "Pharmafile" found in our extensive news archives from over 250 global news sources.

More Information about Pharmafile on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Pharmafile for you to read. Along with our medical data and news we also list Pharmafile Clinical Trials, which are updated daily. BioPortfolio also has a large database of Pharmafile Companies for you to search.

Showing News Articles 1–25 of 872 from Pharmafile

Friday 16th March 2018

Rising levels of opioid prescriptions puts NHS under pressure

It has been found that the number of prescriptions being written for opioid painkillers has risen from 10 million to 23.8 million, from 2007 to 2017. The investigation was conducted by the BBC and has sparked fears that the UK may be heading in a similar direction to the US, which has had to declare a national emergency over opioid abuse. Particularly worrying are the regional differences between ...

NICE recommends Keytruda via CDF as first and only urothelial carcinoma immunotherapy

UK drugs watchdog NICE has published its finance guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS through the Cancer Drugs Fund for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy. The decision makes the drug the first and only immunotherapy to be approved for use on the health service by the a...

Allergan navigating choppy waters, as shares rise and fall

By most measures Allergan has not had the most successful of years and one measure, in particular, is usually indicative of a company’s performance, share price. In this case, Allergan’s shares have been on a steady downward trend, from $239 this time last year to $166 today. There are several reasons for this but the most pressing one for the company is the future of Restasis. It is set to lo...

Hearing drug failure puts biotech on brink

Biotechs with few products in the portfolio are always at a risk should results come back flat, it often leads to them taking negative results and finding a way to examine the data to find a new angle to take the drug back into the clinic. This was the case with Auris Medical, with it hoping that it could be a case of second time lucky when it sent its tinnitus drug back into Phase 3 trials, despi...

Thursday 15th March 2018

BMS restructure will transfer 90 jobs from NY state to Massachusetts and New Jersey

Bristol-Myers Squibb has announced plans to relocate around 90 roles from the state of New York to facilities in Massachusetts and New Jersey as part of a restructuring effort. While the exact number of roles to be moved is still to be confirmed, the company’s pharmaceutical plant in DeWitt will see the loss of employees, transferred to Devens and Central New jersey, where the firm has several f...

Solid Biosciences rocked by clinical hold, shareholders flee

Solid Biosciences raised more than a few eyebrows when it only revealed a partial hold from the FDA stalling its lead prospect on the day of its IPO. This didn’t stop investors flocking to the biotech on the promise of a potential treatment for Duchenne Muscular Dystrophy, which saw its share price rocket from $16 to a peak of $33 in just over a month. read more

Fat-fighting pharma business files for bankruptcy

Orexigen Therapeutics, a biotech that was one of a wave of companies bringing through weight-loss pills, has announced that it has filed for bankruptcy. The company struggled to convince healthcare professionals of the safety and value of its treatment, known as Contrave, leading to struggling sales and an insupportable level of debt. The biotech had initially cruised to a big pharma partnership,...

Andrew Witty takes on a new CEO position

Andrew Witty, who made his name working his way up the ranks at GSK to become its CEO, has revealed his next move after retiring from the position, by becoming CEO at Optum, part of the UnitedHealth Group. The new position will see him switch from being head of a pharma company to being at the forefront of those that play the role as intermediaries in the US healthcare system, pharmacy benefit ma...

Top 5 Reasons Why You Should Attend Veeva R&D Summit, Europe

Veeva R&D Summit, Europe is an annual gathering of pharma, biotech and medical devices professionals in clinical, regulatory, quality, and IT. Now in its fourth year, the event will be hosted at the Fairmont Rey Juan Carlos I on the 12-14 June in Barcelona, and more than 350 delegates are expected to attend. The agenda features dedicated tracks focused on driving end-to-end business proce...

Wednesday 14th March 2018

Teva denies wrongdoing in Cephalon pay-to-delay deal hearing

Teva has denied allegations from the European Commission (EC) that it engaged in illegal anti-competitive pay-to-delay tactics to maintain its market share in the sleep disorder drug space at a hearing this week, it has emerged. read more

Hammond suggests NHS may receive cash boost

The pressures on the NHS over the winter months exposed serious cracks in the service, with issues regarding underfunding, struggles to recruit enough staff and overcrowded hospitals all being widely reported. The Chancellor of Exchequer, Philip Hammond, eventually released additional funds to the service in his Autumn budget, with an additional £2.8 billion provided to the service over the next ...

US "right to try" experimental drug bill defeated in House vote

The divisive and much-talked-about “right to try” legislation designed to provide access for terminally ill Americans to experimental and unproven drugs has been defeated on the House floor by predominantly Democrat opposition after failing to secure the majority vote of two-thirds to successfully pass, with 259 for and 140 against. Image caption:  ...

World’s first synthetic, non-biologic vaccine developed

One of the major challenges in delivering vaccinations to all parts of the globe is the need to keep the temperature regulated, with vaccines needing to stay at a cool temperature no matter the climate of the region in which they are transported. Researchers from Cardiff University may have discovered a way to bypass this challenge, by creating the world’s first synthetic, non-biologic vaccine f...

Tuesday 13th March 2018

AbbVie secures further strong results for potential blockbuster

AbbVie’s elagolix has been slated as a blockbuster-in-the-making by analysts predicting big things for the potential treatment for uterine fibroids and endometriosis. Hopes on this front have been boosted by further Phase 3 results that have indicated that AbbVie stands in a good position to go in front of the FDA for an indication in uterine fibroids. read more

FDA inspection reveals cGMP issues at Biocon's major Malaysia facility

Biocon’s insulin production facility in Johar, Malaysia – the largest integrated insulin manufacturing facility in Asia – has been slapped with six observations from the US FDA following an inspection which took place between the 6 and 15 February. Image caption:  Image Credit: Hemant Mishra/Mint read more

Adaxis-AZ immunotherapy combo hit by clinical hold after death

Adaxis and AstraZeneca announced that they had agreed a combination program for axalimogene filolisbac and Imfinzi, respectively, back in 2014 to explore the possibility of treating HPV-associated cervical cancer and HPV-associated head and neck cancer. The news on that front had gone quiet until now, with Adaxis announcing that a patient death in trials had led to a clinical hold being imposed by...

Anthera pulls the plug on Sollpura after Phase 3 failure, shares plummet 84%

Anthera Pharmaceuticals has announced that it is to terminate development of its investigational pancreatic enzyme replacement therapy (PERT) Sollpura after it failed to meet its primary endpoint in the treatment of exocrine pancreatic insufficiency due to cystic fibrosis. read more

Novartis reshuffle begins under new CEO

It’s a common strategy that newly appointed CEOs will try to change the direction of the company via rejigging leadership positions. GSK’s Emma Walmsley, for instance, oversaw a number of high-profile appointments in her first year in charge, notably by snagging Luke Miels from fellow UK company, AstraZeneca. read more

Pfizer begins sell-off, shedding CNS drug to Biogen for $590m

Pfizer’s decision to back out of the neuroscience space was a strategic move that send shudders through the entire industry, and the first portfolio ramification has now been realised with the sale of an asset to a rival. Biogen has picked up PF-04958242 for $75 million upfront with an additional $515 million in milestones locked into development and commercialisation successes; Pfizer will also...

Monday 12th March 2018

AstraZeneca's Brilinta proves safety in heart attack patients at Phase 3

AstraZeneca has revealed new Phase 3 data on its direct-acting P2Y12 receptor antagonist Brilinta (ticagrelor) at the American College of Cardiology’s 67th Annual Scientific Session in Orlando, showing that the drug met its primary endpoint in heart attack patients treated with pharmacological thrombolysis. read more

Impax agrees to $35 million settlement over anticompetitive practices with Valeant generic

Impax Pharmaceuticals has acquiesced to paying a $35 million settlement in order to resolve part of an antitrust lawsuit it is facing related to allegations that it entered into an agreement to delay its own generic version of Valeant’s acne medication Solodyn from hitting the market. read more

Martin Shkreli sentenced to seven years in jail for securities fraud

Three years after he became “the most hated man in America” overnight for jacking up the price of life-saving HIV-related toxoplasmosis drug Daraprim by 5,000%, Martin Shkreli has now been sentenced to seven years in jail for charges of securities fraud. As his price-hiking antics, while highly immoral, were not actually illegal, they were not included in the charges levied against him. ...

Sanofi and Regeneron reveal strong data and a price drop for Praluent

Sanofi and Regeneron have revealed strong new data for its PCSK9 inhibitor Praluent showing the first-ever reduction in deaths within the drug class and a strong reduction in cardiovascular risk, as well as plans to encourage insurers to cover the product and maximise access for patients. read more

Hikma's Advair generic delayed in the US

Hikma Pharmaceuticals has been knocked back with the news that the FDA has delayed approval of its generic lung treatment for lack of data, it has emerged, which is good news for GlaxoSmithKline, manufacturer of the reference product Advair, who will be able to avoid increased competition in the space for a little while longer. read more

Friday 9th March 2018

GSK loses £37m appeal over pay-to-delay tactics to block Seroxat competition

GlaxoSmithKline has suffered a sizeable blow after losing an appeal disputing that it had engaged in anti-competitive pay-to-delay tactics to block generic versions of its blockbuster antidepressant Seroxat (paroxetine) from reaching the market. read more

Quick Search


News Quicklinks